BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 3.07.2025

FDA Clears Path for SYNDROS (Dronabinol) Solution Approval

The FDA has determined that SYNDROS (dronabinol) solution, 5 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs).

Source: Federal Register — Food and Drug AdministrationOpen original release →